A Phase 2, Open Label, Multi-center Study to Assess the Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-Small Cell Lung Cancer With EGFR Common Mutations
Overview
- Phase
- Phase 2
- Intervention
- JMT101 Injection
- Conditions
- Local Advanced or Metastatic NSCLC
- Sponsor
- Shanghai JMT-Bio Inc.
- Enrollment
- 161
- Locations
- 1
- Primary Endpoint
- Adverse events incidence and severity
- Status
- Active, not recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
This was a multicenter, open-label phase 2 study. This study aimed to evaluate the efficacy and safety of JMT101 combined with Osimertinib in participants with local advanced or metastatic non-small-cell lung cancer harbouring EGFR common mutation with or without prior systemic therapy.
Efficacy indexes included investigator-assessed Overall Response Rate(ORR), Disease Control Rate(DCR), Duration of Response( DoR), Progression Free Survival (PFS) per RECIST 1.1 and Overall Survival (OS). Safety indexes included Adverse Events incidence and severity. This study included 4 cohorts, cohort 1 included EGFR-mutated advanced NSCLC patients without prior systemic therapy and accepted JMT101 6mg/Kg Q3W and Osimertinib 80mg QD therapy. Cohort 2 included EGFR-mutated advanced NSCLC patients who failed with prior generation 1 or 2 EGFR-TKIs therapy and accepted JMT101 6mg/Kg Q2W and Osimertinib 80mg QD therapy. Cohort 3 included advanced EGFR common mutation NSCLC patients who failed with prior generation 3 EGFR-TKIs but did not accept chemotherapy and accepted JMT101 6mg/Kg Q2W and Osimertinib 80mg or 160mg QD therapy. Cohort 4 included EGFR-mutated advanced EGFR NSCLC patients who failed with prior generation 3 EGFR-TKIs and platinum-based chemotherapy and accepted JMT101 6mg/Kg Q2W and Osimertinib 80mg or 160mg QD therapy.
Detailed Description
Avoid duplicating information that will be entered elsewhere, such as Eligibility Criteria or Outcome Measures.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age between 18-75 years old.
- •Histologically or cytologically confirmed diagnosis of NSCLC, locally advanced (Stage IIIB and IIIC according to the 8th edition of the AJCC TNM staging criteria) or metastatic (Stage IV) harbouring EGFR common mutation with tumour tissue/blood sample. For cohort 1, should not receive prior systemic therapy, for cohort 2, should fail with generation 1 or 2 EGFR-TKIs therapy, for cohort 3, should fail with generation 3 EGFR-TKIs therapy but did not accept chemotherapy, for cohort 4, patients should fail with generation 3 and platinum-based chemotherapy.
- •At least 1 measurable lesion per RECIST Version 1.
- •Life expectancy ≥ 12 weeks.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 to
- •Adequate organ and hematologic function
- •Women with fertility tested negative for blood pregnancy within 7 days prior to trial screening; Any male or female patients with fertility must agree to use effective contraceptive methods throughout the entire trial period and within six months after the end of the trial.
- •Patients must give informed consent to this study before the trial and voluntarily sign a written informed consent form.
Exclusion Criteria
- •Previously received EGFR monoclonal antibody therapy.
- •Have received anti-tumor treatments such as chemotherapy, biological therapy, targeted therapy, immunotherapy, etc. within 4 weeks prior to the first use of the study drug.
- •Have undergone major organ surgery (excluding biopsy) or experienced significant trauma within 4 weeks prior to the first use of the study drug.
- •Have received other clinical study drugs within 4 weeks prior to the first use of the study drug.
- •Known hypersensitivity or intolerance to any component of the study drug or its excipients.
- •Those who use strong or moderate CYP3A4 inducers within 14 days before the first administration of the study drug.
- •The adverse reactions of previous anti-tumor treatments have not yet recovered to CTCAE 5.0 evaluation ≤ level 1 except for toxicity such as alocepia, which is judged to be of no safety risk by researchers;
- •Central nervous system metastasis or meningeal metastasis with clinical symptoms.
- •Having a history of autoimmune diseases, immunodeficiency, including HIV testing positive, or having other acquired or congenital immunodeficiency diseases, or having a history of organ transplantation.
- •Active hepatitis B (hepatitis B virus titer\>1000 copies/mL or 200 IU/mL); Hepatitis C virus and syphilis infections.
Arms & Interventions
JMT101 combined with Osimertinib
JMT101 6mg/kg iv Q2W or Q3W, osimertinib 80mg or 160mg po QD until a treatment discontinuation criterion is met.
Intervention: JMT101 Injection
JMT101 combined with Osimertinib
JMT101 6mg/kg iv Q2W or Q3W, osimertinib 80mg or 160mg po QD until a treatment discontinuation criterion is met.
Intervention: Osimertinib tablet
Outcomes
Primary Outcomes
Adverse events incidence and severity
Time Frame: Up to approximately 60 months after the first participant was enrollment
Overall Response Rate（ORR）per RECST 1.1
Time Frame: Up to approximately 60 months after the first participant was enrollment
Secondary Outcomes
- Overall Survival (OS)(Up to approximately 60 months after the first participant was enrollment)
- Duration of Response (DoR) per RECST 1.1(Up to approximately 60 months after the first participant was enrollment)
- Progression Free Survival (PFS) per RECIST 1.1(Up to approximately 60 months after the first participant was enrollment)
- Disease Control Rate (DCR) per RECST 1.1(Up to approximately 60 months after the first participant was enrollment)